Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining carboplatin and topotecan in
treating patients with relapsed acute myelogenous leukemia.